Inaktiver Wert

Andere Sprachen aTyr Pharma Inc Nasdaq

Aktien

US0021201035

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference	15.05.
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	14.05.
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	14.05.
ATyr Pharma to Present at Upcoming Investor Conferences	06.05.
Atyr Pharma: Q1 Earnings Snapshot	02.05.
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	02.05.
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	02.05.
ATyr Pharma to Participate in April Investor Conferences	01.04.
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Atyr Pharma: Q4 Earnings Snapshot	14.03.
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14.03.
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28.02.
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21.02.
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21.02.
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29.01.
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	18.01.
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	13.11.
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen aTyr Pharma Inc Nasdaq

Aktien

US0021201035

Andere Sprachen

Filter